XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Stock Information for XTL Biopharmaceuticals Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XTL Biopharmaceuticals Ltd.

XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Entered Definitive Agreement to Acquire The Social Proxy
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals - Fundamental Analysis, Key Performance Indications
XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update
XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.